PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
The main objective of this study is to determine the feasibility of the combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) and to determine the best dose of bortezomib to combine with two trastuzumab schedules, weekly and 3-weekly.
Carcinoma Breast Stage IV
DRUG: Combination of trastuzumab and PS-341
Feasibility and maximum tolerated dose, Combination of Velcade and Herceptine in breast metastatic patients, before recurrence|Time of recurrence, safety and tolerability of combinaison before recurrence of metastatic breast cance, time of recurrence
Response rate, Tolerability and safety of combination of velcade and Herceptine, time before response rate
Phase 1 study to determine the feasibility of the combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) given either weekly or 3-weekly.

Additionally, hints about efficacy of the combination will be looked upon.